2024
Final study analysis of PRINT: Prostate cancer intensive, non–cross-reactive therapy for CRPC.
Liaw B, Joshi H, Sheng T, Tsao C, Galsky M, Bakst R, Stewart R, Stock R, Oh W. Final study analysis of PRINT: Prostate cancer intensive, non–cross-reactive therapy for CRPC. Journal Of Clinical Oncology 2024, 42: 147-147. DOI: 10.1200/jco.2024.42.4_suppl.147.Peer-Reviewed Original ResearchPSA response rateAlkaline phosphatase levelsStudy regimenImproved time to disease progressionPhosphatase levelsTime to disease progressionStandard managementResponse rateTreatment of mCRPCBaseline alkaline phosphatase levelsProlonged disease controlMinimize treatment toxicitySignificant antitumor responsesPrevent drug resistanceLong-term suppressionMedian TTPAntitumor responseMedian followTreatment toxicityPrimary endpointProstate cancerSecondary endpointsMCRPCTreatment regimenHeterogeneous disease
2020
PRINT: Prostate cancer intensive, non-cross reactive therapy for CRPC—Early observations of efficacy.
Liaw B, Tsao C, Galsky M, Bakst R, Stewart R, Stock R, Oh W. PRINT: Prostate cancer intensive, non-cross reactive therapy for CRPC—Early observations of efficacy. Journal Of Clinical Oncology 2020, 38: e17575-e17575. DOI: 10.1200/jco.2020.38.15_suppl.e17575.Peer-Reviewed Original ResearchTime to progressionMedian time to PSA progressionSequencing of therapeutic agentsTime to PSA progressionTime-to-progression analysisPSA response rateTreatment of mCRPCMinimize treatment toxicityPrevent drug resistanceLong-term suppressionObservations of efficacyPSA progressionMedian followRestarting therapyAntitumor benefitRadium-223Study regimenTreatment toxicityStudy regimensPrimary endpointProstate cancerMCRPCTherapy completionDrug resistanceRegimen
2019
PRINT: Prostate cancer intensive, non-cross reactive therapy for CRPC—Early observations of feasibility and efficacy.
Liaw B, Tsao C, Galsky M, Bakst R, Stewart R, Stock R, Oh W. PRINT: Prostate cancer intensive, non-cross reactive therapy for CRPC—Early observations of feasibility and efficacy. Journal Of Clinical Oncology 2019, 37: 310-310. DOI: 10.1200/jco.2019.37.7_suppl.310.Peer-Reviewed Original ResearchPrimary endpointMedian time to PSA progressionTime to PSA progressionTime to disease progressionPSA response rateTreatment of mCRPCMinimize treatment toxicityPrevent drug resistancePSA progressionMedian followAntitumor benefitMonthly regimenRadium-223Bone metastasesTreatment toxicityStudy regimensProstate cancerMCRPCHeterogeneous diseaseDrug resistanceDisease progressionWeeks durationDelay progressionResponse ratePatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply